Cite
PIN21 - The Cost-Effectiveness Analysis of Elbasvir/Grazoprevir Versus Peginterferon Αlpha-2A in Combination with Ribavirin in Patients with Chronic Hepatitis C Genotype 1b Infection in China.
MLA
Chen, Py, et al. “PIN21 - The Cost-Effectiveness Analysis of Elbasvir/Grazoprevir Versus Peginterferon Αlpha-2A in Combination with Ribavirin in Patients with Chronic Hepatitis C Genotype 1b Infection in China.” Value in Health, vol. 21, Sept. 2018, p. S65. EBSCOhost, https://doi.org/10.1016/j.jval.2018.07.486.
APA
Chen, P., Liu, Q., Li, H., & Ma, A. (2018). PIN21 - The Cost-Effectiveness Analysis of Elbasvir/Grazoprevir Versus Peginterferon Αlpha-2A in Combination with Ribavirin in Patients with Chronic Hepatitis C Genotype 1b Infection in China. Value in Health, 21, S65. https://doi.org/10.1016/j.jval.2018.07.486
Chicago
Chen, Py, Q Liu, Hc Li, and Ax Ma. 2018. “PIN21 - The Cost-Effectiveness Analysis of Elbasvir/Grazoprevir Versus Peginterferon Αlpha-2A in Combination with Ribavirin in Patients with Chronic Hepatitis C Genotype 1b Infection in China.” Value in Health 21 (September): S65. doi:10.1016/j.jval.2018.07.486.